Asia Pacific Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

List of Tables

The Asia Pacific glioma treatment market is expected to grow from US$ 754.97 million in 2022 to US$ 1,538.88 million by 2030. It is estimated to grow at a CAGR of 9.3% from 2022 to 2030.

Increasing Opportunities in Emerging Economies Fuels Asia Pacific Glioma Treatment Market

Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world. The healthcare sectors in these countries, as well as other developing economies, are projected to expand rapidly in the coming years. The expected growth is ascribed to changes in customer demand, an increase in awareness about healthcare services, and a continuous rise in the aging population. The global brain cancer diagnostics market is likely to grow significantly in the coming years with the proliferation of the healthcare sector. Further, increased government spending on healthcare facilities and consumer purchasing power contribute to the growth of the healthcare sector in developing countries.

Asian countries are witnessing continuous growth in their scientific capabilities, owing to the ongoing clinical research studies, centralized healthcare institutions, well-qualified and highly motivated workforces, and excellent clinical trial facilities. Further, many countries in Asia Pacific have a large and diverse patient pool, with ~60% of the global population residing in the region. Treatment guidelines prepared by regulatory bodies in the US and EU are followed in Asia Pacific for treating diseases, which offers solid prospects for significant and rapid patient recruitment. Thus, the growing healthcare sector in developing countries in Asia Pacific creates better opportunities for the Asia Pacific glioma treatment market players to expand their business.

Asia Pacific Glioma Treatment Market Overview

The Asia Pacific glioma treatment market in Asia Pacific is expected to grow at the fastest CAGR during the forecast period; China, India, and Japan are three major contributors to the market growth in this region. The market is mainly driven by increasing investments by the government and private sectors of the respective countries. A rise in collaborations among Asian countries and Western countries for the development of treatment, increasing demand for brain cancer treatments, and rising prevalence of brain tumors are a few of the key factors that are likely to drive the Asia Pacific glioma treatment market in this region during the forecast period.

China is a country with a vast population and has flourished healthcare infrastructure. The extent of social and economic development differs between the coastal area and rural areas. In the coastal regions, healthcare resources are relatively well developed and readily available compared to the rural areas in the west. Like any other developed and developing country, Japan also focuses on strengthening its healthcare system and providing better access to health systems to its citizens. The government is encouraging advancements in genomic testing through various programs and institutes. Moreover, the increasing geriatric population and the surging prevalence of brain tumors are expected to contribute to the development of the Asia Pacific glioma treatment market.

Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Glioma Treatment Market Segmentation

The Asia Pacific glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the Asia Pacific glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the Asia Pacific glioma treatment market in 2022.

Based on treatment type, the Asia Pacific glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the Asia Pacific glioma treatment market in 2022.

Based on grade, the Asia Pacific glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the Asia Pacific glioma treatment market in 2022.

Based on end user, the Asia Pacific glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the Asia Pacific glioma treatment market in 2022.

Based on country, the Asia Pacific glioma treatment market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific glioma treatment market.

Product Code: BMIRE00029266

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Glioma Treatment Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Government Funding for Glioma Treatment
- 4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
- 4.3.1 Advancements in Healthcare Sector in Emerging Economies
4.4 Future Trends
- 4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:

5. Glioma Treatment Market - Asia Pacific Market Analysis

5.1 Asia Pacific Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

6.1 Overview
6.2 Asia Pacific Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
- 6.3.1 Overview
- 6.3.2 Astrocytoma: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
- 6.4.1 Overview
- 6.4.2 Oligoastrocytoma: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
- 6.5.1 Overview
- 6.5.2 Oligodendroglioma: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

7.1 Overview
7.2 Asia Pacific Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
- 7.3.1 Overview
- 7.3.2 Surgery: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
- 7.4.1 Overview
- 7.4.2 Chemotherapy: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
- 7.5.1 Overview
- 7.5.2 Radiation Therapy: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

8.1 Overview
8.2 Asia Pacific Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
- 8.3.1 Overview
- 8.3.2 Low Grade: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 Grade I: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Grade II: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
- 8.4.1 Overview
- 8.4.2 High Grade: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 Grade III: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.2 Grade IV: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Asia Pacific Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
- 9.3.1 Overview
- 9.3.2 Hospital & Clinics: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: Asia Pacific Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Glioma Treatment Market - Country Analysis

10.1 Overview
- 10.1.1 Asia Pacific Glioma Treatment Market, by Country
  - 10.1.1.1 China
    - 10.1.1.1.1 China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.1.2 China: Asia Pacific Glioma Treatment Market, by Disease
    - 10.1.1.1.3 China: Asia Pacific Glioma Treatment Market, by Treatment Type
    - 10.1.1.1.4 China: Asia Pacific Glioma Treatment Market, by Grade
    - 10.1.1.1.4.1 China: Asia Pacific Glioma Treatment Market, by Low Grade
    - 10.1.1.1.4.2 China: Asia Pacific Glioma Treatment Market, by High Grade
    - 10.1.1.1.5 China: Asia Pacific Glioma Treatment Market, by End User
  - 10.1.1.2 Japan
    - 10.1.1.2.1 Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.2.2 Japan: Asia Pacific Glioma Treatment Market, by Disease
    - 10.1.1.2.3 Japan: Asia Pacific Glioma Treatment Market, by Treatment Type
    - 10.1.1.2.4 Japan: Asia Pacific Glioma Treatment Market, by Grade
    - 10.1.1.2.4.1 Japan: Asia Pacific Glioma Treatment Market, by Low Grade
    - 10.1.1.2.4.2 Japan: Asia Pacific Glioma Treatment Market, by High Grade
    - 10.1.1.2.5 Japan: Asia Pacific Glioma Treatment Market, by End User
  - 10.1.1.3 India
    - 10.1.1.3.1 India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.3.2 India: Asia Pacific Glioma Treatment Market, by Disease
    - 10.1.1.3.3 India: Asia Pacific Glioma Treatment Market, by Treatment Type
    - 10.1.1.3.4 India: Asia Pacific Glioma Treatment Market, by Grade
    - 10.1.1.3.4.1 India: Asia Pacific Glioma Treatment Market, by Low Grade
    - 10.1.1.3.4.2 India: Asia Pacific Glioma Treatment Market, by High Grade
    - 10.1.1.3.5 India: Asia Pacific Glioma Treatment Market, by End User
  - 10.1.1.4 South Korea
    - 10.1.1.4.1 South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.4.2 South Korea: Asia Pacific Glioma Treatment Market, by Disease
    - 10.1.1.4.3 South Korea: Asia Pacific Glioma Treatment Market, by Treatment Type
    - 10.1.1.4.4 South Korea: Asia Pacific Glioma Treatment Market, by Grade
    - 10.1.1.4.4.1 South Korea: Asia Pacific Glioma Treatment Market, by Low Grade
    - 10.1.1.4.4.2 South Korea: Asia Pacific Glioma Treatment Market, by High Grade
    - 10.1.1.4.5 South Korea: Asia Pacific Glioma Treatment Market, by End User
  - 10.1.1.5 Australia
    - 10.1.1.5.1 Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.5.2 Australia: Asia Pacific Glioma Treatment Market, by Disease
    - 10.1.1.5.3 Australia: Asia Pacific Glioma Treatment Market, by Treatment Type
    - 10.1.1.5.4 Australia: Asia Pacific Glioma Treatment Market, by Grade
    - 10.1.1.5.4.1 Australia: Asia Pacific Glioma Treatment Market, by Low Grade
    - 10.1.1.5.4.2 Australia: Asia Pacific Glioma Treatment Market, by High Grade
    - 10.1.1.5.5 Australia: Asia Pacific Glioma Treatment Market, by End User
  - 10.1.1.6 Rest of Asia Pacific
    - 10.1.1.6.1 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Disease
    - 10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Treatment Type
    - 10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Grade
    - 10.1.1.6.4.1 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Low Grade
    - 10.1.1.6.4.2 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by High Grade
    - 10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by End User

11. Asia Pacific Glioma Treatment Market Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Merck & Co Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Sun Pharmaceutical Industries Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Amgen Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Teva Pharmaceutical Industries Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Pfizer Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Amneal Pharmaceuticals Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Biocon Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms